Literature DB >> 29157399

The Dynamics of the Gut Microbiome in Multiple Sclerosis in Relation to Disease.

Ellen M Mowry1, Justin D Glenn2.   

Abstract

Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of unknown etiology, although genetic components and environmental triggers are thought to collude to commence pathogenesis. Numerous investigations are now demonstrating the role of the gut microbiota in neuroinflammation and how alterations in its content may be associated with MS disease. This article explores the studies using MS rodent models to determine the roles of gut bacteria in neuroinflammatory disease, evaluate the evidence linking gut bacterial dysbiosis and MS, and give insight into potential MS therapies targeting the gut microbiota currently under investigation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Experimental autoimmune encephalomyelitis; Gut bacteria; Gut microbiome; Multiple sclerosis; Neuroinflammation

Mesh:

Year:  2018        PMID: 29157399     DOI: 10.1016/j.ncl.2017.08.008

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  8 in total

1.  Simvastatin Therapy in Multiple Sclerosis Patients with Respect to Gut Microbiome-Friend or Foe?

Authors:  Mehdi Toghi; Sara Bitarafan
Journal:  J Neuroimmune Pharmacol       Date:  2019-10-18       Impact factor: 4.147

Review 2.  Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives.

Authors:  Fengna Chu; Mingchao Shi; Yue Lang; Donghui Shen; Tao Jin; Jie Zhu; Li Cui
Journal:  Mediators Inflamm       Date:  2018-04-02       Impact factor: 4.711

3.  A Gut Feeling: A Hypothesis of the Role of the Microbiome in Attention-Deficit/Hyperactivity Disorders.

Authors:  Xue Ming; Neil Chen; Carly Ray; Gretchen Brewer; Jeffrey Kornitzer; Robert A Steer
Journal:  Child Neurol Open       Date:  2018-07-11

4.  Lactobacillus acidipiscis Induced Regulatory Gamma Delta T Cells and Attenuated Experimental Autoimmune Encephalomyelitis.

Authors:  Saisai Ren; Xiaorong Zhang; Hongbing Guan; Lihong Wu; Miao Yu; Dan Hou; Yongyong Yan; Xuechun Fang
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

5.  Decreased abundance of Akkermansia after adrenocorticotropic hormone therapy in patients with West syndrome.

Authors:  Lu Xu; Dandan Chen; Congying Zhao; Lihua Jiang; Shanshan Mao; Chao Song; Feng Gao
Journal:  BMC Microbiol       Date:  2021-04-23       Impact factor: 3.605

Review 6.  Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Authors:  Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-07-06       Impact factor: 5.749

7.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

8.  Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial.

Authors:  Gara Arteaga-Henríquez; Silvia Karina Rosales-Ortiz; Alejandro Arias-Vásquez; Istvan Bitter; Ylva Ginsberg; Pol Ibañez-Jimenez; Tünde Kilencz; Catharina Lavebratt; Silke Matura; Andreas Reif; Janos Rethelyi; Vanesa Richarte; Nanda Rommelse; Anne Siegl; J Antoni Ramos-Quiroga
Journal:  Trials       Date:  2020-02-11       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.